Literature DB >> 24390766

Conceptualizing and prioritizing clinical trial outcomes from the perspectives of people with Parkinson's disease versus health care professionals: a concept mapping study.

Catharina Sjödahl Hammarlund1, Maria H Nilsson, Markus Idvall, Scott R Rosas, Peter Hagell.   

Abstract

BACKGROUND: Focusing clinical investigations on outcomes that are meaningful from an end-user perspective is central in clinical research, particularly in chronic disorders such as Parkinson's disease (PD). However, little is known about how end-users such as people with PD (PwPD) and health care professionals (HCPs) view and prioritize therapeutic outcomes.
PURPOSE: To compare the perspectives of PwPD and HCPs regarding prioritized areas for outcome measurement in clinical PD trials.
METHODS: Concept mapping was used to identify prioritized outcomes (statements) through focus groups (n = 27; 12 PwPD, 12 HCPs, three researchers), statement sorting and importance rating (n = 38; 19 PwPD, 19 HCPs), followed by quantitative (multidimensional scaling, cluster analysis, procrustes analysis) and qualitative analysis.
RESULTS: Sorting of 99 statements by PwPD and HCPs yielded 2D maps (PwPD/HCPs stress values, 0.31/0.21) with eight clusters per group. The correlation between raw sorting data of PwPD and HCPs was 0.80, and there was a significant concordance (m 12 = 0.53; P < 0.001; i.e., r = 0.68) between the spatial arrangements in their respective maps. Qualitatively, the maps from the two groups represented partially different perspectives. There were no significant differences between PwPD and HCP item importance ratings.
CONCLUSION: Although similarities dominated, there were differences in how the relationships between items were perceived by the two groups, emanating from different perspectives, i.e., the clinical biomedical ("disease") versus the lived experience ("illness"). This study illustrates the clinical importance of attention to the perspective of PwPD; taking this into account is likely to provide evidence from clinical investigations that are meaningful and interpretable for end-users.

Entities:  

Mesh:

Year:  2014        PMID: 24390766     DOI: 10.1007/s11136-013-0614-3

Source DB:  PubMed          Journal:  Qual Life Res        ISSN: 0962-9343            Impact factor:   4.147


  28 in total

1.  The 39-Item Parkinson's Disease Questionnaire (PDQ-39): Is it a Unidimensional Construct?

Authors:  Peter Hagell; Maria H Nilsson
Journal:  Ther Adv Neurol Disord       Date:  2009-07       Impact factor: 6.570

Review 2.  The suitability of patient-based measures in the field of Parkinson's disease: a systematic review.

Authors:  Brenda L Den Oudsten; Guus L Van Heck; Jolanda De Vries
Journal:  Mov Disord       Date:  2007-07-30       Impact factor: 10.338

Review 3.  The psychometric properties and clinical utility of measures of walking and mobility in neurological conditions: a systematic review.

Authors:  Sarah Tyson; Louise Connell
Journal:  Clin Rehabil       Date:  2009-09-28       Impact factor: 3.477

4.  Patients have their say on research priorities.

Authors:  David Holmes
Journal:  Lancet Neurol       Date:  2011-10       Impact factor: 44.182

5.  How well do multivariate data sets match? The advantages of a Procrustean superimposition approach over the Mantel test.

Authors:  Pedro R Peres-Neto; Donald A Jackson
Journal:  Oecologia       Date:  2001-10-01       Impact factor: 3.225

6.  Disease versus illness in general practice.

Authors:  C G Helman
Journal:  J R Coll Gen Pract       Date:  1981-09

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  Individualized assessment of quality of life in idiopathic Parkinson's disease.

Authors:  Mark A Lee; Richard W Walker; Anthony J Hildreth; Wendy M Prentice
Journal:  Mov Disord       Date:  2006-11       Impact factor: 10.338

9.  Whose quality of life? Ethical implications in patient-reported health outcome measurement.

Authors:  Peter Hagell; Jan Reimer; Per Nyberg
Journal:  Value Health       Date:  2009-01-12       Impact factor: 5.725

10.  SF-36 includes less Parkinson Disease (PD)-targeted content but is more responsive to change than two PD-targeted health-related quality of life measures.

Authors:  Carlos A Brown; Eric M Cheng; Ron D Hays; Stefanie D Vassar; Barbara G Vickrey
Journal:  Qual Life Res       Date:  2009-08-28       Impact factor: 4.147

View more
  6 in total

1.  A comparison of three methods to generate a conceptual understanding of a disease based on the patients' perspective.

Authors:  Louise Humphrey; Thomas Willgoss; Andrew Trigg; Stephanie Meysner; Mary Kane; Sally Dickinson; Helen Kitchen
Journal:  J Patient Rep Outcomes       Date:  2017-12-19

2.  The Impact of Living with Parkinson's Disease: Balancing within a Web of Needs and Demands.

Authors:  Catharina Sjödahl Hammarlund; Albert Westergren; Ingrid Åström; Anna-Karin Edberg; Peter Hagell
Journal:  Parkinsons Dis       Date:  2018-07-29

3.  Developing human rights based indicators to support country monitoring of rehabilitation services and programmes for people with disabilities: a study protocol.

Authors:  Dimitrios Skempes; Jerome Bickenbach
Journal:  BMC Int Health Hum Rights       Date:  2015-09-24

4.  Understanding help-seeking intentions in male military cadets: An application of perceptual mapping.

Authors:  Sarah Bauerle Bass; Javier Muñiz; Thomas F Gordon; Laurie Maurer; Freda Patterson
Journal:  BMC Public Health       Date:  2016-05-17       Impact factor: 3.295

5.  Understanding side effects of therapy for myasthenia gravis and their impact on daily life.

Authors:  Elizabeth Dansie Bacci; Karin S Coyne; Jiat-Ling Poon; Linda Harris; Audra N Boscoe
Journal:  BMC Neurol       Date:  2019-12-21       Impact factor: 2.474

6.  Ethical Aspects of Personal Science for Persons with Parkinson's Disease: What Happens When Self-Tracking Goes from Selfcare to Publication?

Authors:  Sara Riggare; Maria Hägglund; Annelien L Bredenoord; Martijn de Groot; Bastiaan R Bloem
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.